Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Aquinox raises $25mm through Series B round

Executive Summary

Aquinox Pharmaceuticals Inc. (therapies for cancer and inflammatory, blood, and immune diseases) raised $25mm through its Series B round. New investor Pfizer Venture Investments was joined by returning backers Johnson & Johnson Development Corp., Baker Brothers Investments, and BC Advantage Funds. Aquinox will use the proceeds to advance its lead candidate AQX1125 into Phase I and II trials for blood and immune conditions.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies